-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cogent Biosciences, Inc. (NASDAQ:COGT) to Post FY2023 Earnings of ($2.52) Per Share, Jefferies Financial Group Forecasts
Cogent Biosciences, Inc. (NASDAQ:COGT) to Post FY2023 Earnings of ($2.52) Per Share, Jefferies Financial Group Forecasts
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) – Analysts at Jefferies Financial Group cut their FY2023 earnings per share estimates for Cogent Biosciences in a research note issued on Tuesday, March 14th. Jefferies Financial Group analyst E. Yang now forecasts that the technology company will post earnings of ($2.52) per share for the year, down from their prior estimate of ($2.24). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.15) per share. Jefferies Financial Group also issued estimates for Cogent Biosciences' FY2024 earnings at ($2.26) EPS, FY2025 earnings at ($2.29) EPS and FY2026 earnings at ($1.45) EPS.
Get Cogent Biosciences alerts:Several other equities research analysts also recently weighed in on the company. Needham & Company LLC decreased their target price on Cogent Biosciences from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Wednesday. SVB Leerink upped their target price on Cogent Biosciences from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Thursday, January 5th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $26.00 target price on shares of Cogent Biosciences in a research report on Wednesday.
Cogent Biosciences Trading Down 2.6 %
COGT stock opened at $11.46 on Friday. Cogent Biosciences has a 12-month low of $3.79 and a 12-month high of $18.07. The stock has a 50-day moving average price of $13.36 and a two-hundred day moving average price of $13.25. The company has a market cap of $525.10 million, a PE ratio of -4.68 and a beta of 1.75.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC boosted its holdings in Cogent Biosciences by 43.5% in the third quarter. SG Americas Securities LLC now owns 24,467 shares of the technology company's stock valued at $365,000 after purchasing an additional 7,418 shares during the last quarter. MetLife Investment Management LLC raised its stake in Cogent Biosciences by 45.4% during the third quarter. MetLife Investment Management LLC now owns 34,018 shares of the technology company's stock valued at $508,000 after buying an additional 10,628 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Cogent Biosciences during the third quarter valued at approximately $59,881,000. Metropolitan Life Insurance Co NY raised its stake in Cogent Biosciences by 46.2% during the third quarter. Metropolitan Life Insurance Co NY now owns 3,857 shares of the technology company's stock valued at $58,000 after buying an additional 1,218 shares in the last quarter. Finally, Perceptive Advisors LLC raised its stake in Cogent Biosciences by 3.8% during the third quarter. Perceptive Advisors LLC now owns 3,207,441 shares of the technology company's stock valued at $47,855,000 after buying an additional 118,469 shares in the last quarter.
About Cogent Biosciences
(Get Rating)
Cogent Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Featured Articles
- Get a free copy of the StockNews.com research report on Cogent Biosciences (COGT)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
纳斯达克(代码:COGT-GET Rating)-杰富瑞金融集团的分析师在3月14日星期二发布的一份研究报告中下调了对科兴生物科学公司2023财年每股收益的预期。杰富瑞金融集团分析师E.Yang现在预测,这家科技公司今年的每股收益将为2.52美元,低于此前预测的2.24美元。对Cogent Biosciences目前全年收益的普遍估计是每股2.15美元。杰富瑞金融集团还发布了Cogent Biosciences 2024财年每股收益(2.26美元)、2025财年每股收益(2.29美元)和2026财年每股收益(1.45美元)的预期。
到达令人信服的生物科学警报:其他几位股票研究分析师最近也对该公司进行了分析。Needham&Company LLC在周三的一份研究报告中将Cogent Biosciences的目标价从24.00美元下调至23.00美元,并为该公司设定了“买入”评级。SVB Leerink在1月5日(星期四)的一份研究报告中将Cogent Biosciences的目标价从18.00美元上调至20.00美元,并给予该股“跑赢大盘”的评级。最后,古根海姆在周三的一份研究报告中重申了买入评级,并对Cogent Biosciences的股票发布了26.00美元的目标价。
令人信服的生物科学股下跌2.6%
上周五,COGT股价开盘报11.46美元。Coent Biosciences的股价为3.79美元,为12个月低点,12个月高位为18.07美元。该股的50日移动均线价格为13.36美元,200日移动均线价格为13.25美元。该公司市值为5.251亿美元,市盈率为-4.68倍,贝塔系数为1.75。
机构资金流入和流出
机构投资者和对冲基金最近买卖了该公司的股票。SG America Securities LLC在第三季度将其在Cogent Biosciences的持有量增加了43.5%。SG America Securities LLC现在拥有24,467股这家科技公司的股票,价值365,000美元,上个季度又购买了7,418股。大都会人寿投资管理有限责任公司在第三季度将其在Cogent Biosciences的持股增加了45.4%。大都会人寿投资管理公司现在拥有34,018股这家科技公司的股票,价值508,000美元,上个季度又购买了10,628股。Ra Capital Management L.P.在第三季度收购了Cogent Biosciences的新股份,价值约59,881,000美元。纽约大都会人寿保险公司在第三季度将其在Cogent Biosciences的持股增加了46.2%。纽约大都会人寿保险公司目前持有这家科技公司3,857股股票,价值58,000美元,此前该公司在上个季度又购买了1,218股。最后,感知顾问有限责任公司在第三季度将其在Cogent Biosciences的持股增加了3.8%。感知顾问公司现在拥有3,207,441股这家科技公司的股票,价值47,855,000美元,上个季度又购买了118,469股。
关于Cogent Bioscions
(获取评级)
科金特生物科学公司是一家临床阶段的生物制药公司,致力于基因定义疾病的精确疗法的开发和商业化。它的重点是CGT9486,一种选择性酪氨酸激酶抑制剂,旨在有效地抑制KIT D816V突变以及KIT外显子17的其他突变。
专题文章
- 免费获取StockNews.com关于Cogent Biosciences(COGT)的研究报告
- 这项具有巨大增长前景的小型技术正在接近买入点
- 不要追逐联邦快递更高,等待回调
- 防御性科技投资组合的3只股票
- 从这3头现金母牛身上榨取分红
- 欧洲加息,美联储应该效仿吗?
获得《Cogent Bioscions Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cogent Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧